Research programme: patched hedgehog receptor - Curis
Latest Information Update: 30 May 2007
At a glance
- Originator Curis
- Developer Brigham and Womens Hospital; Curis; Dana-Farber Cancer Institute; Nonindustrial source; University of California at San Francisco
- Class
- Mechanism of Action Signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Basal cell cancer; Brain cancer
Most Recent Events
- 19 May 2003 No development reported - Preclinical for Basal cell cancer in USA (unspecified route)
- 19 May 2003 No development reported - Preclinical for Brain cancer in USA (unspecified route)
- 31 Oct 2000 Ontogeny has merged with Creative BioMolecules and Reprogenesis to form Curis